Jeffrey S Wagener
Overview
Explore the profile of Jeffrey S Wagener including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1592
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States
Rubin J, Thayer S, Watkins A, Wagener J, Hodgkins P, Schechter M
Curr Med Res Opin
. 2017 Jan;
33(4):667-674.
PMID: 28058864
Background: Information is limited regarding the cost of pulmonary exacerbations (PEx) among patients with cystic fibrosis in the United States. Methods: To examine PEx costs, medical chart data were linked...
12.
Konstan M, Pasta D, Wagener J, VanDevanter D, Morgan W
J Cyst Fibros
. 2016 Dec;
16(1):158-160.
PMID: 27916550
Background: Body mass index (BMI) is currently emphasized for evaluating nutritional status in children with cystic fibrosis (CF). Weight for age (WFA) and height for age (HFA) may get less...
13.
Liou T, Jensen J, Allen S, Brayshaw S, Brown M, Chatfield B, et al.
BMJ Open Diabetes Res Care
. 2016 May;
4(1):e000183.
PMID: 27158517
Objective: Cystic fibrosis (CF)-related diabetes (CFRD) is associated with increased morbidity and mortality. Improved detection and management may improve outcomes; however, actual practice falls short of published guidelines. We studied...
14.
Suthoff E, Bonafede M, Limone B, OCallaghan L, Sawicki G, Wagener J
J Med Econ
. 2016 Apr;
19(9):845-51.
PMID: 27074519
Objective: Ivacaftor was approved in 2012 to treat patients with cystic fibrosis (CF) with specific CFTR gene mutations. The objective of this analysis was to analyze the impact of ivacaftor...
15.
Morgan W, VanDevanter D, Pasta D, Foreman A, Wagener J, Konstan M
J Pediatr
. 2015 Sep;
169:116-21.e2.
PMID: 26388208
Objective: To evaluate several alternative measures of forced expiratory volume in 1 second percent predicted (FEV1 %pred) variability as potential predictors of future FEV1 %pred decline in patients with cystic...
16.
Sawicki G, McKone E, Pasta D, Millar S, Wagener J, Johnson C, et al.
Am J Respir Crit Care Med
. 2015 Jul;
192(7):836-42.
PMID: 26132840
Rationale: In clinical trials, patients with cystic fibrosis and a G551D mutation who received ivacaftor experienced improvements in pulmonary and nutritional outcomes. However, whether these improvements reflect a change in...
17.
Wagener J, Elkin E, Pasta D, Schechter M, Konstan M, Morgan W
J Cyst Fibros
. 2014 Dec;
14(3):376-83.
PMID: 25498960
Background: Assessing cystic fibrosis (CF) patient quality of care requires the choice of an appropriate outcome measure. We looked systematically and in detail at pulmonary function outcomes that potentially reflect...
18.
Wagener J, Woo M, Pasta D, Konstan M, Morgan W
J Pediatr Gastroenterol Nutr
. 2014 Jun;
59(4):476-9.
PMID: 24897167
Objectives: The aim of the present article was to determine the prevalence of liver involvement in Hispanic patients with cystic fibrosis (CF) and identify associations with age and severity of...
19.
Kupfer O, Ridall L, Hoffman L, Dishop M, Soep J, Wagener J, et al.
Pediatrics
. 2013 Oct;
132(5):e1445-8.
PMID: 24127476
Pulmonary hemorrhage can be classified as either proximal or distal (alveolar). Causes of proximal hemorrhage include infection, foreign body aspiration, pulmonary embolus, trauma, vascular malformation, and pulmonary hypertension. Causes of...
20.
Konstan M, Wagener J, Pasta D, Millar S, Morgan W
Pediatr Pulmonol
. 2013 Sep;
49(6):529-36.
PMID: 24019211
Objectives: Tobramycin inhalation solution (TIS; TOBI®) has improved forced expiratory volume in 1 sec (FEV1 ) in cystic fibrosis (CF) trials. Using data from the Epidemiologic Study of CF (ESCF),...